Shares of BioScrip Inc. (NASDAQ:BIOS) fell 1.1% on Monday . The company traded as low as $2.65 and last traded at $2.70, with a volume of 326,783 shares trading hands. The stock had previously closed at $2.73.

Separately, Zacks Investment Research upgraded BioScrip from a “sell” rating to a “hold” rating in a research report on Friday, June 17th.

The company has a 50-day moving average price of $2.64 and a 200-day moving average price of $2.41. The firm’s market cap is $312.03 million.

BioScrip (NASDAQ:BIOS) last released its quarterly earnings data on Monday, August 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.09) by $0.05. The firm earned $232.50 million during the quarter, compared to the consensus estimate of $229.58 million. The firm’s revenue was down 11.4% compared to the same quarter last year. On average, equities research analysts expect that BioScrip Inc. will post ($0.27) EPS for the current year.

In other news, Director David W. Golding purchased 12,500 shares of the company’s stock in a transaction that occurred on Friday, June 17th. The stock was acquired at an average cost of $2.48 per share, with a total value of $31,000.00. Following the acquisition, the director now owns 42,500 shares in the company, valued at approximately $105,400. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Coliseum Capital Management, L purchased 4,200,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 22nd. The shares were purchased at an average cost of $2.00 per share, with a total value of $8,400,000.00. The disclosure for this purchase can be found here.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.